Active Cancer Lungs & Breathing

Total Neoadjuvant Treatment in Oesophageal Adenocarcinoma: The TNT-OAC trial feasibility study

Funder CSO (part of Scottish Govt)
Recipient organisation University of Dundee
Funding £349K
Period Oct 2025 — Sept 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

Research project funded by CSO at University of Dundee.

View the original record at the funder ↗

Researchers

Russel Petty (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

The spatially-resolved oesophageal adenocarcinoma response to high and standard dose radiotherapy
Endoscopic Management of Patients with T1bN0M0 Esophageal Adenocarcinoma: a Prospective Multicenter Registry
A multicentre, open-label, non-randomized, phase Ib, neoadjuvant study of intravenous dosing of NG-641, an oncolytic adenoviral vector expressing a fibroblast activation protein-directed bi-specific T-cell activator antibody fragment (FAP-TAc) and an immune enhancer module (CXCL9/CXCL10/interferon alpha2), as monotherapy or in combination with pembrolizumab in patients with surgically resectable squamous cell carcinoma of the head and neck (Mode Of Action Transgene study- MOAT)
The PREFER Study: Endoscopic management of patients with T1bN0M0 oesophageal adenocarcinoma: a prospective multicentre registry study.
OCTAVE - Ovarian Cancer Trial with an Enhanced Group B Oncolytic Adenovirus

Original classification

None

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.